| pubmed-article:7769838 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7769838 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7769838 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:7769838 | lifeskim:mentions | umls-concept:C0039902 | lld:lifeskim |
| pubmed-article:7769838 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:7769838 | lifeskim:mentions | umls-concept:C0444889 | lld:lifeskim |
| pubmed-article:7769838 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:7769838 | pubmed:dateCreated | 1995-7-6 | lld:pubmed |
| pubmed-article:7769838 | pubmed:abstractText | 6-Thioguanine (6-TG) was administered as a continuous i.v. infusion for 7 days to 24 patients with relapsed or refractory acute leukemia or in the blast phase of chronic granulocytic leukemia. The daily dose of 6-TG was escalated from 37.5 mg/m2 to 160 mg/m2. Stomatitis was dose-related and dose-limiting with a maximum tolerated dose of 120 mg/m2 daily. Cutaneous reactions were dose-related but not dose-limiting. The recommended dose for phase II trials in acute leukemia is 120 mg/m2 per day as a continuous infusion for 7 days. There were two complete and four partial remissions among all patients. At the suggested phase II dose of 120 mg/m2 there were two complete remissions and one partial remission in five evaluable patients. | lld:pubmed |
| pubmed-article:7769838 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7769838 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7769838 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7769838 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7769838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7769838 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7769838 | pubmed:month | May | lld:pubmed |
| pubmed-article:7769838 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:PowellB LBL | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:CooperM RMR | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:CruzJ MJM | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:LyerlyE SES | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:HurdD DDD | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:ChorleyH MHM | lld:pubmed |
| pubmed-article:7769838 | pubmed:author | pubmed-author:MotsingerC... | lld:pubmed |
| pubmed-article:7769838 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7769838 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:7769838 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7769838 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7769838 | pubmed:pagination | 770-3 | lld:pubmed |
| pubmed-article:7769838 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:meshHeading | pubmed-meshheading:7769838-... | lld:pubmed |
| pubmed-article:7769838 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7769838 | pubmed:articleTitle | Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia. | lld:pubmed |
| pubmed-article:7769838 | pubmed:affiliation | Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC 27157-1082, USA. | lld:pubmed |
| pubmed-article:7769838 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7769838 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7769838 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7769838 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
